NCT05814107CompletedPhase 1
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-996 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 28 Nov 2025
Brief summary (registry, in English)
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- First submitted
- 23 Feb 2023
- Start date
- 9 May 2023
- Primary completion date
- 7 Nov 2025
- Lead sponsor
- Carmot Australia First Pty Ltd
- Diseases
- Obesity, Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT05814107
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 94
- From 9 May 2023 to the primary completion date, 7 Nov 2025
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of alcoholism or drug addiction within 1 year prior to Screening
Other illness
- History of significant medical conditions and malignancy
- Uncontrollable hypertension
Other
- Current or recent participation in an investigational clinical trial
Who the study is looking for
- Participants 18-65 years old, inclusive
- BMI of 25 - 40, inclusive
- Stable body weight for two months
- Additional Inclusion Criterion for Part 3 (MD T2DM cohorts) only:
- Participants in Part 3 should have a documented diagnosis of Type 2 Diabetes Mellitus (T2DM)
- Participants in Part 3 should have glycated hemoglobin (HbA1c) between 7.0% and 10.0%
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nucleus Network Pty Ltd Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| Avant Santé Research Center S.A. de C.V. Coordinator of this site? Confirm its status | San Pedro Garza García | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.